Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
Tumors or cancer of the THYROID GLAND.

Stimulation of thymidine uptake and cell proliferation in mouse embryo fibroblasts by conditioned medium from mammary cells in culture. (1/4288)

Undialyzed conditioned medium from several cell culture sources did not stimulate thymidine incorporation or cell overgrowth in quiescent, density-inhibited mouse embryo fibroblast cells. However, dialyzed conditioned medium (DCM) from clonal mouse mammary cell lines MCG-V14, MCG-T14, MCG-T10; HeLa cells; primary mouse adenocarcinoma cells; and BALB/c normal mouse mammary epithelial cells promoted growth in quiescent fibroblasts. The amount of growth-promoting activity produced per cell varied from 24% (HeLa) to 213% (MCG-V14) of the activity produced by primary tumor cells. The production of growth-promoting activity was not unique to tumor-derived cells or cells of high tumorigenicity. The amount of growth-promoting activity produced per cell in the active cultures was not correlated with any of the following: tumorigenicity, growth rat, cell density achieved at saturation, cell type, or species of cell origin. It is concluded that transformed and non-transformed cells of diverse origin, cell type, and tumorigenicity can produce growth factors in culture. The growth-promoting potential of the active media from primary tumor cultures accumulated with time of contact with cells and was too great to be accounted for entirely by the removal of low-molecular-weight inhibitors by dialysis. The results are consistent with the hypothesis that conditioned medium from the active cultures contained a dialyzable, growth-promoting activity. Different cell lines exhibited differential sensitivity to tumor cell DCM and fetal bovine serum. Furthermore, quiescent fibroblasts were stimulated by primary tumor cell DCM in the presence of saturating concentrations of fetal bovine serum. These observations support the notion that the active growth-promoting principle in primary tumor cell DCM may not be a serum factor(s).  (+info)

Isolation and purification of rat mammary tumor peroxidase. (2/4288)

7,12-Dimethylbenz(a)anthracene-induced rat mammary tumors often contain high levels of the enzyme perioxidase, a putative marker of estrogen dependence. This enzyme can be effectively extracted with 0.5 M CaCl2, giving rise to a soluble peroxidase with a molecular weight of about 50,000 as determined by gel filtration. This is the same size as the estrogen-induced peroxidase of rat uterus but smaller than other mammalian peroxidases. Further purification of the rat mammary tumor peroxidase by concanavalin A-Sepharose chromatography and hydrophobic interaction chromatography on phenyl Sepharose provides a 640-fold purification of the enzyme.  (+info)

Unsaturated fatty acid requirements for growth and survival of a rat mammary tumor cell line. (3/4288)

A cell line, the growth and survival of which is markedly affected by linoleic acid, has been established from a carcinogen-induced rat mammary tumor. The cells have been continuously passaged in 5% rat serum plus 10% fetal calf serum-supplemented medium. The rat serum component was found to be indispensalbe, for when it was omitted the growth rate rapidly declined and the cells died by 5 to 7 days. Removal of the rat serum from the growth medium also resulted in a dramatic loss of Oil Red O-positive droplets in the cells, suggesting that the lipid component of rat serum might be a major growth-promoting principle in rat serum. This is likely since the total lipid fraction, but not the delipidized protein fraction, could largely supplant requirement of the cells for rat serum. Pure linoleic acid was found to be effective in maintaining the cell growth in delipidized serum or in whole fetal calf serum-supplemented medium. Fatty acid analysis revealed a 19-fold higher amount of linoleic acid in rat serum than in fetal calf serum.  (+info)

Vasopressin stimulation of acetate incorporation into lipids in a dimethylbenz(a)anthracene-induced rat mammary tumor cell line. (4/4288)

In a preliminary report we described the effects of rat prolactin on the incorporation of [14C]acetate into lipids by a cell line from a dimethylbenz(a)anthracene-induced rat mammary tumor. The characteristics of the response to prolactin were very similar to those described for the normal rat mammary gland; namely, insulin was required for full expression of the response, maximal activity was not seen until 36 hr after the addition of the hormones, and growth hormone was able to elicit the same response. However, we were unable to detect binding of 125I-labeled prolactin to these cells, and furthermore, other more purified prolactin preparations were inactive. Upon further investigation we discovered that the activity resided in a low-molecular-weight fraction of the rat prolactin B-1 preparation and was probably either vasopressin or oxytocin or both. These data suggest the possibility that vasopressin may play a role in rodent mammary tumorigenesis.  (+info)

Glucocorticoid down-regulation of fascin protein expression is required for the steroid-induced formation of tight junctions and cell-cell interactions in rat mammary epithelial tumor cells. (5/4288)

Glucocorticoid hormones, which are physiological regulators of mammary epithelium development, induce the formation of tight junctions in rat Con8 mammary epithelial tumor cells. We have discovered that, as part of this process, the synthetic glucocorticoid dexamethasone strongly and reversibly down-regulated the expression of fascin, an actin-bundling protein that also interacts with the adherens junction component beta-catenin. Ectopic constitutive expression of full-length mouse fascin containing a Myc epitope tag (Myc-fascin) in Con8 cells inhibited the dexamethasone stimulation of transepithelial electrical resistance, disrupted the induced localization of the tight junction protein occludin and the adherens junction protein beta-catenin to the cell periphery, and prevented the rearrangement of the actin cytoskeleton. Ectopic expression of either the carboxyl-terminal 213 amino acids of fascin, which includes the actin and beta-catenin-binding sites, or the amino-terminal 313 amino acids of fascin failed to disrupt the glucocorticoid induction of tight junction formation. Mammary tumor cells expressing the full-length Myc-fascin remained generally glucocorticoid responsive and displayed no changes in the levels or protein-protein interactions of junctional proteins or the amount of cytoskeletal associated actin filaments. However, a cell aggregation assay demonstrated that the expression of Myc-fascin abrogated the dexamethasone induction of cell-cell adhesion. Our results implicate the down-regulation of fascin as a key intermediate step that directly links glucocorticoid receptor signaling to the coordinate control of junctional complex formation and cell-cell interactions in mammary tumor epithelial cells.  (+info)

Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. (6/4288)

Overexpression of the HER-2/neu proto-oncogene, which encodes the tyrosine kinase receptor p185neu, has been observed in tumors from breast cancer patients. We demonstrated previously that emodin, a tyrosine kinase inhibitor, suppresses tyrosine kinase activity in HER-2/neu-overexpressing breast cancer cells and preferentially represses transformation phenotypes of these cells in vitro. In the present study, we examined whether emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and whether emodin can sensitize these tumors to paclitaxel, a commonly used chemotherapeutic agent for breast cancer patients. We found that emodin significantly inhibited tumor growth and prolonged survival in mice bearing HER-2/neu-overexpressing human breast cancer cells. Furthermore, the combination of emodin and paclitaxel synergistically inhibited the anchorage-dependent and -independent growth of HER-2/neu-overexpressing breast cancer cells in vitro and synergistically inhibited tumor growth and prolonged survival in athymic mice bearing s.c. xenografts of human tumor cells expressing high levels of p185neu. Both immunohistochemical staining and Western blot analysis showed that emodin decreases tyrosine phosphorylation of HER-2/neu in tumor tissue. Taken together, our results suggest that the tyrosine kinase activity of HER-2/neu is required for tumor growth and chemoresistance and that tyrosine kinase inhibitors such as emodin can inhibit the growth of HER-2/neu-overexpressing tumors in mice and also sensitize these tumors to paclitaxel. The results may have important implications in chemotherapy for HER-2/neu-overexpressing breast tumors.  (+info)

Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. (7/4288)

Endoglin (EDG, CD105) is a proliferation-associated antigen on endothelial cells. In this study, two new anti-EDG monoclonal antibodies (mAbs) Y4-2F1 (or termed SN6j) and P3-2G8 (SN6k) were generated and used for treating distinct preformed tumors. These mAbs, both IgG1-kappa antibodies, cross-reacted weakly with mouse endothelial cells but defined epitopes different from the epitope defined by a previously reported anti-EDG mAb K4-2C10 (B. K. Seon et al., Clin. Cancer Res., 3: 1031-1044, 1997). SN6j and SN6k reacted strongly with human endothelial cells and vascular endothelium of malignant human tissues but showed no significant reactivity with tumor cells per se. The deglycosylated ricin A chain (dgRA) conjugates of the two mAbs showed a weak but specific cytotoxic activity against murine endothelial cells in vitro. In the therapeutic studies, severe combined immunodeficient mice were inoculated s.c. with MCF-7 human breast cancer cells and left untreated until palpable tumors of distinct size (4-6 mm in diameter) appeared. Mice with the distinct tumors were treated by i.v. administration of individual anti-EDG conjugates, unconjugated mAbs, or a control conjugate. Long-lasting complete regression of the tumors was induced in the majority of tumor-bearing mice (n = 8 for each conjugate) when 40 microg of the individual conjugates were administered three times via the tail vein. It is remarkable that the tumors remained regressed without further therapy for as long as the mice were followed (i.e., 100 days). Control conjugate did not induce regression of the tumors in any of the treated mice, although weak nonspecific effects were observed in some of the mice (n = 8). The effects of unconjugated mAbs were small with the dose used, i.e., 34 microg three times. The anti-EDG conjugates showed antiangiogenic activity in the dorsal air sac assay in mice. The results suggest good potential of these conjugates for the clinical application.  (+info)

Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. (8/4288)

BACKGROUND: Tamoxifen and the citrus flavonoid tangeretin exhibit similar inhibitory effects on the growth and invasive properties of human mammary cancer cells in vitro; furthermore, the two agents have displayed additive effects in vitro. In this study, we examined whether tangeretin would enhance tamoxifen's therapeutic benefit in vivo. METHODS: Female nude mice (n = 80) were inoculated subcutaneously with human MCF-7/6 mammary adenocarcinoma cells. Groups of 20 mice were treated orally by adding the following substances to their drinking water: tamoxifen (3 x 10(-5) M), tangeretin (1 x 10(-4) M), tamoxifen plus tangeretin (3 x 10(-5) M plus 1 x 10(-4) M), or solvent. RESULTS AND CONCLUSIONS: Oral treatment of mice with tamoxifen resulted in a statistically significant inhibition of tumor growth compared with solvent treatment (two-sided P = .001). Treatment with tangeretin did not inhibit tumor growth, and addition of this compound to drinking water with tamoxifen completely neutralized tamoxifen's inhibitory effect. The median survival time of tumor-bearing mice treated with tamoxifen plus tangeretin was reduced in comparison with that of mice treated with tamoxifen alone (14 versus 56 weeks; two-sided P = .002). Tangeretin (1 x 10(-6) M or higher) inhibited the cytolytic effect of murine natural killer cells on MCF-7/6 cells in vitro, which may explain why tamoxifen-induced inhibition of tumor growth in mice is abolished when tangeretin is present in drinking water. IMPLICATIONS: We describe an in vivo model to study potential interference of dietary compounds, such as flavonoids, with tamoxifen, which could lead to reduced efficacy of adjuvant therapy. In our study, the tumor growth-inhibiting effect of oral tamoxifen was reversed upon addition of tangeretin to the diet. Our data argue against excessive consumption of tangeretin-added products and supplements by patients with mammary cancer during tamoxifen treatment.  (+info)

Mammary neoplasms in animals refer to abnormal growths or tumors that occur in the mammary glands. These tumors can be benign (non-cancerous) or malignant (cancerous). Benign tumors are slow growing and rarely spread to other parts of the body, while malignant tumors are aggressive, can invade surrounding tissues, and may metastasize to distant organs.

Mammary neoplasms are more common in female animals, particularly those that have not been spayed. The risk factors for developing mammary neoplasms include age, reproductive status, hormonal influences, and genetic predisposition. Certain breeds of dogs, such as poodles, cocker spaniels, and dachshunds, are more prone to developing mammary tumors.

Clinical signs of mammary neoplasms may include the presence of a firm, discrete mass in the mammary gland, changes in the overlying skin such as ulceration or discoloration, and evidence of pain or discomfort in the affected area. Diagnosis is typically made through a combination of physical examination, imaging studies (such as mammography or ultrasound), and biopsy with histopathological evaluation.

Treatment options for mammary neoplasms depend on the type, size, location, and stage of the tumor, as well as the animal's overall health status. Surgical removal is often the primary treatment modality, and may be curative for benign tumors or early-stage malignant tumors. Radiation therapy and chemotherapy may also be used in cases where the tumor has spread to other parts of the body. Regular veterinary check-ups and monitoring are essential to ensure early detection and treatment of any recurrence or new mammary neoplasms.

There is no medical definition for "dog diseases" as it is too broad a term. However, dogs can suffer from various health conditions and illnesses that are specific to their species or similar to those found in humans. Some common categories of dog diseases include:

1. Infectious Diseases: These are caused by viruses, bacteria, fungi, or parasites. Examples include distemper, parvovirus, kennel cough, Lyme disease, and heartworms.
2. Hereditary/Genetic Disorders: Some dogs may inherit certain genetic disorders from their parents. Examples include hip dysplasia, elbow dysplasia, progressive retinal atrophy (PRA), and degenerative myelopathy.
3. Age-Related Diseases: As dogs age, they become more susceptible to various health issues. Common age-related diseases in dogs include arthritis, dental disease, cancer, and cognitive dysfunction syndrome (CDS).
4. Nutritional Disorders: Malnutrition or improper feeding can lead to various health problems in dogs. Examples include obesity, malnutrition, and vitamin deficiencies.
5. Environmental Diseases: These are caused by exposure to environmental factors such as toxins, allergens, or extreme temperatures. Examples include heatstroke, frostbite, and toxicities from ingesting harmful substances.
6. Neurological Disorders: Dogs can suffer from various neurological conditions that affect their nervous system. Examples include epilepsy, intervertebral disc disease (IVDD), and vestibular disease.
7. Behavioral Disorders: Some dogs may develop behavioral issues due to various factors such as anxiety, fear, or aggression. Examples include separation anxiety, noise phobias, and resource guarding.

It's important to note that regular veterinary care, proper nutrition, exercise, and preventative measures can help reduce the risk of many dog diseases.

'Mammary neoplasms, experimental' is not a recognized medical term. However, I can provide definitions for the individual terms:

1. Mammary: Pertaining to the breast or mammary glands in females, which are responsible for milk production.
2. Neoplasms: Abnormal growths of tissue, also known as tumors or masses, that can be benign (non-cancerous) or malignant (cancerous).
3. Experimental: Relating to a scientific experiment or study, typically conducted in a controlled setting to test hypotheses and gather data.

In the context of medical research, 'experimental mammary neoplasms' may refer to artificially induced breast tumors in laboratory animals (such as rats or mice) for the purpose of studying the development, progression, treatment, and prevention of breast cancer. These studies can help researchers better understand the biology of breast cancer and develop new therapies and strategies for its diagnosis and management.

Pancreatic neoplasms refer to abnormal growths in the pancreas that can be benign or malignant. The pancreas is a gland located behind the stomach that produces hormones and digestive enzymes. Pancreatic neoplasms can interfere with the normal functioning of the pancreas, leading to various health complications.

Benign pancreatic neoplasms are non-cancerous growths that do not spread to other parts of the body. They are usually removed through surgery to prevent any potential complications, such as blocking the bile duct or causing pain.

Malignant pancreatic neoplasms, also known as pancreatic cancer, are cancerous growths that can invade and destroy surrounding tissues and organs. They can also spread (metastasize) to other parts of the body, such as the liver, lungs, or bones. Pancreatic cancer is often aggressive and difficult to treat, with a poor prognosis.

There are several types of pancreatic neoplasms, including adenocarcinomas, neuroendocrine tumors, solid pseudopapillary neoplasms, and cystic neoplasms. The specific type of neoplasm is determined through various diagnostic tests, such as imaging studies, biopsies, and blood tests. Treatment options depend on the type, stage, and location of the neoplasm, as well as the patient's overall health and preferences.

Neoplasms are abnormal growths of cells or tissues in the body that serve no physiological function. They can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms are typically slow growing and do not spread to other parts of the body, while malignant neoplasms are aggressive, invasive, and can metastasize to distant sites.

Neoplasms occur when there is a dysregulation in the normal process of cell division and differentiation, leading to uncontrolled growth and accumulation of cells. This can result from genetic mutations or other factors such as viral infections, environmental exposures, or hormonal imbalances.

Neoplasms can develop in any organ or tissue of the body and can cause various symptoms depending on their size, location, and type. Treatment options for neoplasms include surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy, among others.

Neoplasms: Neoplasms refer to abnormal growths of tissue that can be benign (non-cancerous) or malignant (cancerous). They occur when the normal control mechanisms that regulate cell growth and division are disrupted, leading to uncontrolled cell proliferation.

Cystic Neoplasms: Cystic neoplasms are tumors that contain fluid-filled sacs or cysts. These tumors can be benign or malignant and can occur in various organs of the body, including the pancreas, ovary, and liver.

Mucinous Neoplasms: Mucinous neoplasms are a type of cystic neoplasm that is characterized by the production of mucin, a gel-like substance produced by certain types of cells. These tumors can occur in various organs, including the ovary, pancreas, and colon. Mucinous neoplasms can be benign or malignant, and malignant forms are often aggressive and have a poor prognosis.

Serous Neoplasms: Serous neoplasms are another type of cystic neoplasm that is characterized by the production of serous fluid, which is a thin, watery fluid. These tumors commonly occur in the ovary and can be benign or malignant. Malignant serous neoplasms are often aggressive and have a poor prognosis.

In summary, neoplasms refer to abnormal tissue growths that can be benign or malignant. Cystic neoplasms contain fluid-filled sacs and can occur in various organs of the body. Mucinous neoplasms produce a gel-like substance called mucin and can also occur in various organs, while serous neoplasms produce thin, watery fluid and commonly occur in the ovary. Both mucinous and serous neoplasms can be benign or malignant, with malignant forms often being aggressive and having a poor prognosis.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Kidney neoplasms refer to abnormal growths or tumors in the kidney tissues that can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various types of kidney cells, including the renal tubules, glomeruli, and the renal pelvis.

Malignant kidney neoplasms are also known as kidney cancers, with renal cell carcinoma being the most common type. Benign kidney neoplasms include renal adenomas, oncocytomas, and angiomyolipomas. While benign neoplasms are generally not life-threatening, they can still cause problems if they grow large enough to compromise kidney function or if they undergo malignant transformation.

Early detection and appropriate management of kidney neoplasms are crucial for improving patient outcomes and overall prognosis. Regular medical check-ups, imaging studies, and urinalysis can help in the early identification of these growths, allowing for timely intervention and treatment.

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Thyroid neoplasms refer to abnormal growths or tumors in the thyroid gland, which can be benign (non-cancerous) or malignant (cancerous). These growths can vary in size and may cause a noticeable lump or nodule in the neck. Thyroid neoplasms can also affect the function of the thyroid gland, leading to hormonal imbalances and related symptoms. The exact causes of thyroid neoplasms are not fully understood, but risk factors include radiation exposure, family history, and certain genetic conditions. It is important to note that most thyroid nodules are benign, but a proper medical evaluation is necessary to determine the nature of the growth and develop an appropriate treatment plan.

... liver neoplasms, experimental MeSH E05.598.500.496.843 - mammary neoplasms, experimental MeSH E05.598.500.496.937 - melanoma, ... experimental MeSH E05.598.500.468 - liver cirrhosis, experimental MeSH E05.598.500.496 - neoplasms, experimental MeSH E05.598. ... experimental MeSH E05.598.500.750 - radiation injuries, experimental MeSH E05.601.123.700 - surface plasmon resonance MeSH ... experimental MeSH E05.598.500.496.968 - sarcoma, experimental MeSH E05.598.500.500 - nervous system autoimmune disease, ...
The most common are adenomas of the pituitary and adenomas/adenocarcinomas of the adrenal cortex in both sexes, mammary gland ... Drachman, R. H.; Root, R. K.; Wood, W. B. (August 1966). "Studies on the effect of experimental nonketotic diabetes mellitus on ... Mac Kenzie, William; Garner, F. (1973). "Comparison of Neoplasms in Six Sources of Rats". JNCI: Journal of the National Cancer ... The Lewis rat suffers from several spontaneous pathologies: first, they can suffer from high incidences of neoplasms, with the ...
The experimental method first developed by Gronowitz et al. used quantities of radioisotope much higher than those used in ... Lipkin M, Deschner E, Troncale F (1970). "Cell differentiation and the development of colonic neoplasms". CA: A Cancer Journal ... and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker". BMC Veterinary Research. 10: 228. doi: ... Experimental and Therapeutic Medicine. 2 (6): 1177-1181. doi:10.3892/etm.2011.338. PMC 3440839. PMID 22977640. Liu Y, Ling Y, ...
... inflammatory bowel disease and experimental autoimmune encephalomyelitis In experimental colitis-induced colon carcinoma, ... "Differential expression of cell surface heparan sulfate proteoglycans in human mammary epithelial cells and lung fibroblasts". ... a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms". American Journal of Clinical ... Advances in Experimental Medicine and Biology. Vol. 313. pp. 69-78. doi:10.1007/978-1-4899-2444-5_7. ISBN 978-1-4899-2446-9. ...
Dunn, Thelma B. "Morphology of Mammary Tumors in Mice" (1958). "Studies of the Mammary-Tumor Agent of Strain RIII Mice". JNCI: ... "Histology of Some Neoplasms and Non-Neo-plastic Lesions Found in Wild Mice Maintained Under Laboratory Conditions". JNCI: ... She developed methods of inducing malignant tumors in the stomachs and intestines of experimental animals and studied the ... "Studies of the Mammary-Tumor Agent of Strain RIII Mice" (1961), "Further Studies of the Mammary Tumor Agent of Strain RIII Mice ...
Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DJ (eds ... ISBN 978-3-642-65806-8. Council on Drugs (1960). "Androgens and estrogens in the treatment of disseminated mammary carcinoma: ... Schnitzer R (1 January 1967). Experimental Chemotherapy. Elsevier Science. pp. 156-. ISBN 978-0-323-14611-1. Krüskemper HL (22 ... "An evaluation of stanolone in treatment of advanced mammary cancer". Journal of the American Medical Association. 154 (15): ...
Smalley MJ, Clarke RB (January 2005). "The mammary gland "side population": a putative stem/progenitor cell marker?". Journal ... Misago N, Narisawa Y (September 2006). "Cytokeratin 15 expression in neoplasms with sebaceous differentiation". Journal of ... Experimental Hematology. 13 (2): 143-50. PMID 2857651. Perron M, Boy S, Amato MA, et al. (April 2003). "A novel function for ... Clarke RB (December 2005). "Isolation and characterization of human mammary stem cells". Cell Proliferation. 38 (6): 375-86. ...
In the absence of specific markers for mammary cells, models with genetic marking of tumor cells gives the best experimental ... It also confirms the genetic heterogeneity between the primary neoplasm of breast cancer patients and their respective ... In the non-fused mouse, the mammary gland would revert to a near virgin, but with this addition the mammary gland maintained ... Whey acidic protein (WAP), is another common promoter used to generate mouse mammary cancer models. For a list of other mammary ...
A Case Report About the Relationship Between Neoplasms of the Mammary-Like-Glands and Hormones". Cureus. 13 (2): e13061. doi: ... Clinical and Experimental Dermatology. 45 (8): 1035-1039. doi:10.1111/ced.14254. PMID 32356582. S2CID 218475319. Pfarr N, Sinn ... "Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma ... Arora K, El-Zaatari ZM, Schwartz MR, Ro JY (August 2020). "Lesions of anogenital mammary-like glands: Four cases including ...
Experimental data also strong supports a pro-oncogenic role for GPER. First, GPER is required for the survival of tumor- ... However, GPER knockout mice show no overt mammary phenotype, unlike ERα knockout mice, but similarly to ERβ knockout mice. This ... Immunohistochemical and transcriptomic analyses of neoplasms derived from a variety of tissues including but not limited to: ... "G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis". Molecular cancer research: MCR. 12 (11): ...
... tracheal neoplasms MeSH C04.588.448.200 - bone marrow neoplasms MeSH C04.588.531.500 - mammary neoplasms, experimental MeSH ... liver neoplasms, experimental MeSH C04.588.274.761 - pancreatic neoplasms MeSH C04.588.274.761.249 - adenoma, islet cell MeSH ... skull base neoplasms MeSH C04.588.149.828 - spinal neoplasms MeSH C04.588.180.260 - breast neoplasms, male MeSH C04.588.180.390 ... bile duct neoplasms MeSH C04.588.274.120.250.250 - common bile duct neoplasms MeSH C04.588.274.120.401 - gallbladder neoplasms ...
Majewska H, Skálová A, Stodulski D, Klimková A, Steiner P, Stankiewicz C, Biernat W. "Mammary analogue secretory carcinoma of ... One patient with ETV6-FLT3-related myeloid/lymphoid neoplasm obtained a short term remission on sunitinib and following relapse ... The Journal of Experimental Medicine. 208 (13): 2571-9. doi:10.1084/jem.20112239. PMC 3244026. PMID 22162831. Sanchez-Martin M ... These cancers include secretory breast cancer (also termed juvenile breast cancer), mammary analogue secretory carcinoma of the ...
Neoplasms occurring in epithelial tissue such as the liver, gastrointestinal tract, and the pancreas have been linked to ... Experimental cancer studies have shown that carbon tetrachloride may cause benign and malignant liver tumors to rainbow trout. ... In females, this includes mammary glands, fallopian tubes, uterus, cervix, and vagina. In males, this includes the prostate, ...
In these cases an involvement of the skin by a noncutaneous internal neoplasm may occur. EMPD occurs due to an invasion of the ... Zhou S, Zhong W, Mai R, Zhang G (2017). "Mammary and Extramammary Paget's Disease Presented Different Expression Pattern of ... International Journal of Clinical and Experimental Pathology. 8 (10): 13233-40. PMC 4680468. PMID 26722523. Anton C, Luiz AV, ... Lopes Filho LL, Lopes IM, Lopes LR, Enokihara MM, Michalany AO, Matsunaga N (April 2015). "Mammary and extramammary Paget's ...
Besides those, reduced CK1δ activity owing to the site N172D mutation of CK1δ decelerated mammary carcinoma progression, and ... Experimental Cell Research. 263 (1): 43-54. doi:10.1006/excr.2000.5100. PMID 11161704. Stöter M, Krüger M, Banting G, Henne- ... hematopoietic malignancies and lymphoid neoplasms. Also decreased CK1δ mRNA expression levels have been observed in some cancer ... Experimental Cell Research. 269 (2): 275-86. doi:10.1006/excr.2001.5324. PMID 11570820. Green CL, Bennett GS (August 1998). " ...
Two broad experimental survey articles also document most of these epigenetic DNA repair deficiencies in cancers. Red- ... Such mutations and epigenetic alterations can give rise to cancer (see malignant neoplasms). Germ line mutations in DNA repair ... Apr 2016). "The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular ... almost one third of miRNA promoters active in normal mammary cells were found hypermethylated in breast cancer cells - that is ...
Roskoski R (2016). "Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms". ... and mouse mammary tumor virus. Given the central role of SYK in transmission of activating signals within B-cells, a ... The Journal of Experimental Medicine. 181 (6): 1997-2006. doi:10.1084/jem.181.6.1997. PMC 2192070. PMID 7539035. Sidorenko SP, ...
STEWART, SE; EDDY, BE; BORGESE, N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ... Guy, CT; Cardiff, RD; Muller, WJ (March 1992). "Induction of mammary tumors by expression of polyomavirus middle T oncogene: a ... Experimental Biology and Medicine. 83 (2): 414-21. doi:10.3181/00379727-83-20376. PMID 13064287. S2CID 34223353. ... "Transgenic Polyoma middle-T mice model premalignant mammary disease". Cancer Research. 61 (22): 8298-305. PMID 11719463. Lin, ...
It originates in a lactiferous duct as opposed to the lobules that form the alveoli in the breasts' mammary glands (lobules ... International Journal of Clinical and Experimental Pathology. 6 (3): 445-57. PMC 3563205. PMID 23412348. Liu XY, Jiang YZ, Liu ... "Overview of the 2022 WHO Classification of Thyroid Neoplasms". Endocrine Pathology. 33 (1): 27-63. doi:10.1007/s12022-022-09707 ... sugar-linked proteins normally produced and secreted by the mammary gland and found in milk). The cells around these spaces and ...
... mammary - mammogram - mammography - Mammotome - mantle field - marimastat - mast cell - mastectomy - mastocytoma - matrix ... neoplasm - nephrotomogram - nephrotoxic - nephroureterectomy - nerve block - nerve grafting - nerve-sparing radical ... unconventional cancer treatments-see experimental cancer treatment - undifferentiated-see cellular differentiation - unilateral ... Hürthle cell neoplasm - hydrazine sulfate - hydromorphone - hydronephrosis - hydroureter - hydroxychloroquine - hydroxyurea - ...
The results of numerous experimental and clinical studies of malignant neoplasms have indicated that invasive growth and ... TGF-β, which acts in the epithelial cells of the mammary gland as a potent tumor suppressor at the early stages of cancer, can ... Experimental data indicates the potential existence of a collective-amoeboid transition, when tumor masses invading surrounding ... The factors limiting the growth of malignant neoplasms include the basement membrane and various components of the surrounding ...
Advances in Experimental Medicine and Biology. Vol. 777. pp. 3-24. doi:10.1007/978-1-4614-5894-4_1. ISBN 9781461458937. PMID ... mammary glands, trachea, salivary glands, uterus, placenta, digestive tract, testes, and some other cell types. Today CD133 is ... "CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas" ( ...
Advances in Experimental Medicine and Biology. Vol. 727. pp. 210-222. doi:10.1007/978-1-4614-0899-4_16. ISBN 978-1-4614-0898-7 ... "Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells". Breast Cancer Research. 6 (6): R605 ... is broken by chromosomal translocations in T lymphoblastic neoplasms". Cell. 66 (4): 649-61. doi:10.1016/0092-8674(91)90111-B. ... Advances in Experimental Medicine and Biology. Vol. 727. pp. 305-319. doi:10.1007/978-1-4614-0899-4_23. ISBN 978-1-4614-0898-7 ...
In the early 1970s, MGA was found to be associated with mammary tumors in beagle dogs, and along with several other ... Frick J, Marberger H, Swoboda HP (May 1971). "[Hormone therapy of prostatic neoplasms]". Der Urologe (in German). 10 (3): 117- ... Goletiani NV, Keith DR, Gorsky SJ (October 2007). "Progesterone: review of safety for clinical studies". Experimental and ... The medication was withdrawn in some countries in 1970 due to concerns about mammary toxicity observed in dogs, but this turned ...
The pre-procedure mammograms were negative for malignant neoplasms. In the 17-patient cohort, it was noted that two women ... Subglandular - The breast implant is emplaced to the retromammary space, between the breast tissue (the mammary gland) and the ... Later, in a letter to the readers, the editors of Analytical Chemistry published their concerns about the faulty experimental ... Hester TR Jr; Tebbetts JB; Maxwell GP (2001). "The Polyurethane-covered Mammary Prosthesis: Facts and Fiction (II): A Look Back ...
Dao TL (1975). "Pharmacology and Clinical Utility of Hormones in Hormone Related Neoplasms". In Sartorelli AC, Johns DG (eds ... Crowley LG, Macdonald I (April 1965). "Delalutin and estrogens for the treatment of advanced mammary carcinoma in the ... Dorfman RI (5 December 2016). Steroidal Activity in Experimental Animals and Man. Elsevier Science. pp. 398-. ISBN 978-1-4832- ... Crowley LG, Macdonald I (1962). "Clinical trial of delautin in the treatment of advanced mammary carcinoma in postmenopausal ...
Rous P (September 1910). "A Transmissible Avian Neoplasm. (Sarcoma of the Common Fowl.)". The Journal of Experimental Medicine ... In 1936 John Joseph Bittner identified the mouse mammary tumor virus, an "extrachromosomal factor" (i.e. virus) that could be ... Experimental and epidemiological data imply a causative role for viruses and they appear to be the second most important risk ... Stewart SE, Eddy BE, Borgese N (June 1958). "Neoplasms in mice inoculated with a tumor agent carried in tissue culture". ...
Male reproductive system - Mammary gland - Mandible - The mandible, lower jaw or jawbone is the largest, strongest and lowest ... Papillary - In oncology, papillary refers to neoplasms with projections ("papillae", from Latin, 'nipple') that have ... The Journal of Experimental Medicine. 135 (3): 675-97. doi:10.1084/jem.135.3.675. PMC 2139142. PMID 4536706. Miyahara S, ... In females, it serves as the mammary gland, which produces and secretes milk to feed infants. Both females and males develop ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... Experimental cancer treatments are studied in clinical trials to compare the proposed treatment to the best existing treatment ... The German professor Wilhelm Fabry believed that breast cancer was caused by a milk clot in a mammary duct. The Dutch professor ...
After experimental SeV infection the virus can replicate and shed from the upper and lower respiratory tract of African green ... Its expression is also increased in a wide range of other malignant neoplasms. Factor X (F10) is frequently expressed in normal ... immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis". Anticancer ... Advances in Experimental Medicine and Biology. Vol. 790. New York, NY. pp. 95-127. doi:10.1007/978-1-4614-7651-1_6. ISBN 978-1- ...
Mammary Neoplasms, Experimental / metabolism* * Mice * Phenols / toxicity* * Polycomb Repressive Complex 2 * Pregnancy ... We examined the effect of BPA and DES on EZH2 expression and function in MCF-7 cells and in mammary glands of mice exposed in ... Mice exposed to DES in utero showed a ,2-fold increase in EZH2 expression in adult mammary tissue compared with controls (p , ... In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an ...
Experimental Mammary Neoplasms IAGP. 1581951. RGD. Experimental Mammary Neoplasms induced. IAGP. XCO:0000090. 1581951. compared ... increased mammary adenocarcinoma incidence IAGP. 1581951. RGD. increased mammary adenocarcinoma incidence induced. IAGP. XCO: ... Only show annotations with direct experimental evidence (0 objects hidden). Term. Qualifier. Evidence. With. Reference. Notes. ... We also investigated allelic imbalance (AI) in mammary carcinomas from (WKy x WF)F1 rats and Mcs7 heterozygous congenics. Of ...
View Rat Genome Database annotations to Experimental Mammary Neoplasms ... An association has been curated linking Mcs15 and Experimental Mammary Neoplasms in Rattus norvegicus. *The association was ... 388 RGD objects have been annotated to Experimental Mammary Neoplasms (DOID:9005233). ...
The study considered each dog as an individual experimental unit for assessing CA 15-3, CRP, LDH, and clinicopathological ... Female canine mammary neoplasms (CMNs) are defined as a heterogeneous group of diseases of complex classification, diagnosis, ... Figure 1 Serum CA 15-3, CRP and LDH concentrations in canine mammary neoplasms (CMNs) and in the control group. *Statistical ... Serum CA 15-3, CRP and LDH concentrations in canine mammary neoplasms (CMNs) and in the control group. *Statistical difference ...
... liver neoplasms, experimental MeSH E05.598.500.496.843 - mammary neoplasms, experimental MeSH E05.598.500.496.937 - melanoma, ... experimental MeSH E05.598.500.468 - liver cirrhosis, experimental MeSH E05.598.500.496 - neoplasms, experimental MeSH E05.598. ... experimental MeSH E05.598.500.750 - radiation injuries, experimental MeSH E05.601.123.700 - surface plasmon resonance MeSH ... experimental MeSH E05.598.500.496.968 - sarcoma, experimental MeSH E05.598.500.500 - nervous system autoimmune disease, ...
Mammary Neoplasms, Experimental. *Cell Line, Tumor. *Cell Hypoxia. Citation. APA Chicago ICMJE ...
Hematologic Neoplasms [C04.588.448] * Mammary Neoplasms, Animal [C04.588.531] * Mammary Neoplasms, Experimental [C04.588. ... MAMMARY NEOPL ANIMAL. Entry Term(s). Animal Mammary Carcinoma Mammary Carcinoma, Animal Mammary Neoplasms Neoplasms, Mammary ... Mammary Neoplasms, Animal Preferred Concept UI. M0024029. Scope Note. Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY ... animal only but MAMMARY NEOPLASMS, EXPERIMENTAL is also available; coord IM with histol type of neopl (IM) + precoord animal/ ...
Mammary Neoplasms, Animal. Receptor, ErbB-3. Apoptosis. Mammary Neoplasms, Experimental. Cell Line, Tumor. Cell Proliferation. ... Triple Negative Breast Neoplasms. Hormone Replacement Therapy. Thyroid Hormones. Neoplasms, Germ Cell and Embryonal. ... Breast Neoplasms. Receptor, ErbB-2. Disease-Free Survival. Tamoxifen. ...
Mammary Neoplasms, Experimental 64.72. × References/Inference Genes * References * Inference genes * 14522882 * 17584969 ...
Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Photosensitizing Agents; Porphyrins; ... Navune, N., Polo, C., Frisardi, A., Batlle, A., Mouse mammary carcinoma PBGase and hydroxymethylbilane synthetase (1991) Comp ... 1988) UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia, , UKCCCR: London ... and photosensitizing efficiency of porphyrins induced by application of exogenous 5-aminolevulinic acid in mice bearing mammary ...
... animal mammary neoplasms; mammary neoplasms, experimental; melanoma; neoplasms, experimental; nevus; melanocytic nevus; stomach ... Potentially involved in: carcinoma; cancer; lipoma; brain neoplasms; freckles; liposarcoma; lymphatic diseases; ... neoplasms; subcutaneous nodule; dry skin; hair abnormalities (non-specific); liposarcoma, dedifferentiated; xerosis; brain stem ...
... fostering its use in an experimental group using learning theories, post experimental assessment and applications. Supervisor: ... Everard, K., Tate, A., Case Report: A Plasma Cell Neoplasm Imitating a Carcinoid. CJP. 2022 Submitted for second review ... Point-Based Weighted Diagnostic Scale for Histopathologic Assessment of Mammary Cellular Fibroepithelial Lesions. Pending ... Investigating the NLRP3 Inflammasome and its Regulator miR-223-3p in Multiple Sclerosis and Experimental Demyelination. 2022 ...
Mammary analogue secretory carcinoma presenting as a salivary gland neoplasm. International Journal of Clinical and ... International Journal of Clinical and Experimental Medicine. 8:15581-15590. * A functional variant at the miRNA binding site in ...
... and mouse mammary tumor virus." Experimental and molecular pathology.. 2001 Jun; 70(3):183-93. ... "Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice." Blood.. 2002 Jul 1; 100(1):238-45. ... "Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB ... "Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4." Oncogene.. 2006 Sep 14; 25(41):5664-72. Epub ...
Mammary Neoplasms, Experimental. *Mastectomy, Segmental. *Mechanical Phenomena. *Medical Records. *Melanins. *Membrane ...
In this study preputial graft has been used for the first time to reconstruct the experimental full- thickness defect of lower ... Histopathological Study of Experimental Grafting of Prepuce to Lower Eyelid in Dogs ...
Tumours of the large intestine, mesotheliomas and hepatoblastomas are rare spontaneous neoplasms in experimental animals. ... It also increased the multiplicity of fibroadenomas of the mammary gland in females. ...
Tumour infiltrating macrophages (TIMs) isolated from primary mammary carcinomas of C3H/Avy mice were cultured on bone slices to ... Animals, Bone Resorption, Cells, Cultured, Macrophages, Macrophages, Alveolar, Mammary Neoplasms, Experimental, Mice, Mice, ... Tumour infiltrating macrophages (TIMs) isolated from primary mammary carcinomas of C3H/Avy mice were cultured on bone slices to ...
Tumours of the large intestine, mesotheliomas and hepatoblastomas are rare spontaneous neoplasms in experimental animals. ... It also increased the multiplicity of fibroadenomas of the mammary gland in females. ...
Animals, CD11b Antigen, Cell Division, Disease Models, Animal, Female, Macrophages, Mammary Neoplasms, Experimental, Mice, ...
Experimental studies had indicated that 1,3-butadiene induced a carcinogenic response in rats and mice at multiple sites. Rats ... exposed at 1,000 to 8,000ppm developed mammary, uterine, Leydig cell, thyroid follicular cell, pancreatic exocrine and Zymbal ... studies indicated that there was a nonstatistically significant excess mortality for lymphatic and hematopoietic neoplasms, and ...
liver neoplasms, experimental MeSH E05.598.500.496.843 - mammary neoplasms, experimental MeSH E05.598.500.496.937 - melanoma ... Liver Neoplasms Entry term(s). Hepatic Neoplasm Hepatic Neoplasms Liver Neoplasm Neoplasm, Hepatic Neoplasm, Liver Neoplasms ... ExperimentalParotid NeoplasmsNeoplasms, Connective and Soft TissueNeoplasms, Plasma CellAppendiceal NeoplasmsOvarian Neoplasms ... ExperimentalLung NeoplasmsDNA, NeoplasmLiver Cirrhosis, AlcoholicCystadenomaNeoplasms, ExperimentalParotid NeoplasmsLiver, ...
In a murine mammary tumour model, we demonstrated that administration of either alpha-GalCer or anti-CD25 antibody alone ... Lung Neoplasms, Lymphocyte Activation, Lymphocyte Depletion, Mammary Neoplasms, Experimental, Mice, Mice, Inbred BALB C, Mice, ... In a murine mammary tumour model, we demonstrated that administration of either alpha-GalCer or anti-CD25 antibody alone ... Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary ...
Mammary Neoplasms, Experimental, Mice, Mice, Nude, Neoplasms, Hormone-Dependent, Ovariectomy, RNA, Small Interfering, Reverse ... 17-Hydroxysteroid Dehydrogenases, Animals, Antineoplastic Agents, Hormonal, Breast Neoplasms, Cell Line, Tumor, Chromatography ...
Establishment and quantitative imaging of a 3D lung organotypic model of mammary tumor outgrowth. Martin, M. D., Fingleton, B. ... Lynch, C. C., Wells, S., McIntyre, J. O., Piston, D. W. & Matrisian, L. M., Dec 2008, In: Clinical and Experimental Metastasis. ...
... and characterizing widely used commercial chemicals in experimental animals are among the most important methods developed in ... Neoplasms, Experimental / chemically induced * Neoplasms, Experimental / history * Rats * Rats, Sprague-Dawley Substances * ... Benzene caused carcinomas of the Zymbal gland, oral cavity, nasal cavities; cancers of the skin, forestomach, mammary glands, ... Maltoni developed experimental methods that have reached the "platinum standard" for protection of public health. Benzene was ...
Background: In recent years increased frequency of mammary gland neoplasms have been reported in captive wild felids. Basing on ... The health care practices followed in experimental area by the respondents viz. use of veterinary facilities, isolation of sick ... A case report of mammary carcinoma in Royal Bengal Tiger. ... The present report describes a case of Mammary carcinoma with ... published data, in tigers mammary gland carcinoma always seems to be highly invasive and metastatic. ...
Because this experimental model develops tumors in the mammary glands approximately 10 weeks after the start of the experiment ... and malignant neoplasms have remained the most common cause of death since 1981. At present, malignant neoplasms are ... Number of rats with mammary tumors per effective number of rats; ‡ Number of mammary tumors per rat; § Tumor volume was ... As a result, the incidence of mammary tumors was reduced by soy milk, but the suppression of mammary carcinogenesis was more ...
  • Consensus regarding the diagnosis, prognosis and treatment of canine and feline mammary tumors-2019. (scielo.br)
  • Sorenmo KU, Worley DR, Zappulli V. Tumors of the Mammary Gland. (scielo.br)
  • Tumors or cancer of the MAMMARY GLAND in animals ( MAMMARY GLANDS, ANIMAL ). (nih.gov)
  • Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. (uams.edu)
  • Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4. (rochester.edu)
  • Early animal experiments involving mice did demonstrate mammary tumors and urogenital changes in males which were found in initial testing prior to NutraSweet approval. (aspartaam.nl)
  • NutraSweet has already been shown to induce mammary tumors and testicular changes in experimental animals. (aspartaam.nl)
  • OBJECTIVE: Salivary gland tumors (SGT) are a diverse group of uncommon neoplasms that are rare in pediatric patients. (bvsalud.org)
  • Although researchers have learned much from the study of this diverse group of tumors over the years, the diagnosis and treatment of salivary gland neoplasms remain complex and challenging problems for the head and neck surgeon. (medscape.com)
  • Salivary gland neoplasms make up 6% of all head and neck tumors. (medscape.com)
  • Benign neoplasms occur more frequently in women than in men, but malignant tumors are distributed equally between the sexes. (medscape.com)
  • Almost half of all submandibular gland neoplasms and most sublingual and minor salivary gland tumors are malignant. (medscape.com)
  • Similarly, fetal exposure to BPA induces neoplastic changes in mammary tissue of mice. (nih.gov)
  • We examined the effect of BPA and DES on EZH2 expression and function in MCF-7 cells and in mammary glands of mice exposed in utero. (nih.gov)
  • EZH2 protein was elevated in mammary tissue of mice exposed to DES or BPA. (nih.gov)
  • Similarly, mice exposed to BPA or DES in utero showed increased mammary histone H3 trimethylation. (nih.gov)
  • Tumour infiltrating macrophages (TIMs) isolated from primary mammary carcinomas of C3H/Avy mice were cultured on bone slices to assess their ability to resorb bone. (ox.ac.uk)
  • Experimental studies had indicated that 1,3-butadiene induced a carcinogenic response in rats and mice at multiple sites. (cdc.gov)
  • Experimental studies in mice were approved by the Creutzfeldt-Jakob institutional animal care and use committee of the American Red Cross Holland Laboratory. (cdc.gov)
  • estimates of vCJD prevalence might be increased by The remaining mice in the vCJD group, including 2 other expanding screening to include samples of lymphoreticular neoplasms. (cdc.gov)
  • The aim of this study was to analyze the effect of indole-3-carbinol on a SCID mice xenograft model of canine inflammatory mammary cancer, using equivalent human oral dose as a preventive therapy in humans for 3 weeks. (biomedcentral.com)
  • In another study, MOCA induced follicular-cell neoplasms of the thyroid gland in rats and hepatocellular carcinomas or adenomas in mice under the tested conditions (104 weeks study). (europa.eu)
  • Developmental programming of EZH2 is a novel mechanism by which in utero exposure to endocrine disruptors leads to epigenetic regulation of the mammary gland. (nih.gov)
  • It also increased the multiplicity of fibroadenomas of the mammary gland in females. (epicwaterfilters.com)
  • Background: In recent years increased frequency of mammary gland neoplasms have been reported in captive wild felids. (cabi.org)
  • Basing on published data, in tigers mammary gland carcinoma always seems to be highly invasive and metastatic. (cabi.org)
  • Esophageal cancer is the common malignant neoplasm, which arises from the mucosa or gland of the esophagus. (biomedcentral.com)
  • Advances in the understanding of may be more susceptible at a par- sembled for IARC Group 1 carcino- host susceptibility in tandem with the ticular site (i.e. the mammary gland gens contains information on mecha- evolution of the knowledge on the in females). (who.int)
  • Pleomorphic adenoma (PA) is the most common salivary gland tumor, accounting for 50%-60% of these neoplasms. (bvsalud.org)
  • Some common salivary gland neoplasms are listed in the image below. (medscape.com)
  • [ 1 ] The incidence of salivary gland neoplasms as a whole is approximately 1.5 cases per 100,000 individuals in the United States. (medscape.com)
  • Salivary gland neoplasms most commonly appear in the sixth decade of life. (medscape.com)
  • Among salivary gland neoplasms, 80% arise in the parotid glands, 10-15% arise in the submandibular glands, and the remainder arise in the sublingual and minor salivary glands. (medscape.com)
  • The most common tumor of the parotid gland is the pleomorphic adenoma , which represents about 60% of all parotid neoplasms, as seen in the image below. (medscape.com)
  • Salivary gland neoplasms are rare in children. (medscape.com)
  • In children, 35% of salivary gland neoplasms are malignant. (medscape.com)
  • The etiology of salivary gland neoplasms is not fully understood. (medscape.com)
  • Recent evidence suggests that the bicellular stem cell theory is the more probable etiology of salivary gland neoplasms. (medscape.com)
  • A case report of mammary carcinoma in Royal Bengal Tiger. (cabi.org)
  • The present report describes a case of Mammary carcinoma with. (cabi.org)
  • Este tumor se originó espontáneamente como carcinoma del pulmón en un ratón C57BL. (bvsalud.org)
  • During the sixth week of development, the mammary glands first develop as solid downgrowths of the epidermis that extend into the mesenchyme from the axilla to the inguinal regions. (medscape.com)
  • Neoplasms that arise in the salivary glands are relatively rare, yet they represent a wide variety of both benign and malignant histologic subtypes as seen in the image below. (medscape.com)
  • Most series report that about 80% of parotid neoplasms are benign, with the relative proportion of malignancy increasing in the smaller glands. (medscape.com)
  • Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. (lookformedical.com)
  • Our data reveal for the first time that the ingestion of indole-3-carbinol, as administered, diminishes proliferation and increases apoptosis of tumor cells in an experimental model of inflammatory breast cancer, although this effect could not be enough to avoid the appearance of tumor embolization and metastasis. (biomedcentral.com)
  • Clinical and Experimental Metastasis. (lu.se)
  • Substances that increase the risk of NEOPLASMS in humans or animals. (lookformedical.com)
  • The aim of this study was to analyze the hypothetical antitumor effect of I3C administration on a SCID mouse xenograft model of canine inflammatory mammary cancer using an equivalent dose to that used as a preventive anti-cancer agent in humans. (biomedcentral.com)
  • Based upon the weight of evidence of carcinogenicity in experimental animals, dichloromethane is classified as "probably carcinogenic to humans", i.e., as a substance for which there is believed to be some chance of adverse health effect at any level of exposure. (canada.ca)
  • VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. (uams.edu)
  • en] Several cell kinetic parameters of the mammary adenocarcinoma EO 771 were evaluated by means of tumor volume measurements and of 125 I-UdR. (iaea.org)
  • Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model. (ox.ac.uk)
  • Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion. (rochester.edu)
  • It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. (lookformedical.com)
  • Differential HIF-1α and HIF-2α Expression in Mammary Epithelial Cells during Fat Pad Invasion, Lactation, and Involution. (lu.se)
  • A primary malignant neoplasm of epithelial liver cells. (lookformedical.com)
  • Research of Malignant Catarrhal Fever has been linked to Malignant Paraganglionic Neoplasm, Malignant Neoplasms, Leukemia, Neoplasms, Malignant Neoplasm Of Breast. (novusbio.com)
  • The Wistar Kyoto (WKy) rat is resistant to mammary carcinomas induced with 7,12-dimethybenz[a]anthracene (DMBA), whereas the Wistar Furth (WF) strain is susceptible. (mcw.edu)
  • We also investigated allelic imbalance (AI) in mammary carcinomas from (WKy x WF)F1 rats and Mcs7 heterozygous congenics. (mcw.edu)
  • In one key study in rats a dose-related incidence by 'MOCA' of chemically-induced neoplasms and pre-neoplastic lesions was observed after 104 weeks fed with a protein adequate or protein deficient diet. (europa.eu)
  • The Mcs7 quantitative trait locus is associated with an increased susceptibility to mammary cancer in congenic rats and an allele-specific imbalance. (mcw.edu)
  • An association has been curated linking Mcs15 and Experimental Mammary Neoplasms in Rattus norvegicus. (mcw.edu)
  • Results of epidemiological studies indicated that there was a nonstatistically significant excess mortality for lymphatic and hematopoietic neoplasms, and leukemia. (cdc.gov)
  • In 2020, approximately 2.3 million new cases were estimated, which corresponds to 11.7% of the total number of diagnosed neoplasms(1). (bvsalud.org)
  • The identification of putative prognostic factors in canine mammary neoplasms (CMNs) has been focused on tissue-specific biomarkers, but the serum biomarkers, including cancer antigen 15-3 (CA 15-3), c-reactive protein (CRP), and lactate dehydrogenase (LDH) have been demonstrated to display clinical application in cases of CMNs. (scielo.br)
  • Female canine mammary neoplasms (CMNs) are defined as a heterogeneous group of diseases of complex classification, diagnosis, and prognosis. (scielo.br)
  • There are no previous studies on its effects in human inflammatory breast cancer or canine inflammatory mammary cancer that is the most aggressive type of breast cancer. (biomedcentral.com)
  • There are no data on the effect of I3C in human inflammatory breast cancer (IBC) or in spontaneous and experimental canine inflammatory mammary cancer (IMC). (biomedcentral.com)
  • Ongoing - Erivwo P , Salama S, Gai L. Mrkonjic M. Armstrong S. Turashvili G. Point-Based Weighted Diagnostic Scale for Histopathologic Assessment of Mammary Cellular Fibroepithelial Lesions. (mun.ca)
  • Tumours of the large intestine, mesotheliomas and hepatoblastomas are rare spontaneous neoplasms in experimental animals. (epicwaterfilters.com)
  • Neoplasms containing cyst-like formations or producing mucin or serum. (lookformedical.com)
  • Cesare Maltoni's contributions to understanding, identifying, and characterizing widely used commercial chemicals in experimental animals are among the most important methods developed in the history of toxicology and serve to protect working men and women, the general population, and our environment from hazardous substances. (nih.gov)
  • This finding has been confirmed numerous times and the DNA-protein-cross-links are believed to cause cancers in experimental animals. (aspartaam.nl)
  • 1984. Experimental atrazine toxicity: Relation between morphofunctional indexes and the presence of residues in the parenchymal tissue of treated animals. (cdc.gov)
  • Local effects in the upper respiratory tract were induced after repeated inhalation exposure in experimental animals. (europa.eu)
  • The overall NOAEC for local effects in experimental animals is 1 ppm (1.2 mg/m³). (europa.eu)
  • To understand associated biological information of (-)-Perillyl alcohol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures. (cmdm.tw)
  • Soon after birth, the nipples are raised from the shallow mammary pits by proliferation of the surrounding connective tissue. (medscape.com)
  • Nowadays, the most common neoplasm in the world is breast cancer. (bvsalud.org)
  • Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. (lookformedical.com)
  • Moore, C., Barron, J ., Manuscript: JNC-2022-0022.R1 Title: Investigating the NLRP3 Inflammasome and its Regulator miR-223-3p in Multiple Sclerosis and Experimental Demyelination. (mun.ca)
  • Despite the increased probability of survival to neoplasms, several conse- quences of the disease and treatment accompany people for a long time, impacting their quality of life(3). (bvsalud.org)
  • Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. (lookformedical.com)
  • In this study preputial graft has been used for the first time to reconstruct the experimental full- thickness defect of lower eyelid in dog. (vin.com)
  • These are rare conditions and results when the mammary ridges fail to develop or completely disappear. (medscape.com)